Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1991 Jan;83(1):92–95. doi: 10.1111/j.1365-2249.1991.tb05594.x

14C1, an antigen associated with human ovarian cancer, defined using a human IgG monoclonal antibody.

G Gallagher 1, F al-Azzawi 1, L P Walsh 1, G Wilson 1
PMCID: PMC1535482  PMID: 1988233

Abstract

We have selected a human EBV-transformed cell line from the involved lymph nodes of an ovarian cancer patient which secretes an IgG1 kappa antibody, able to recognize an antigen present on the surface of ovarian cancer cells. The antigen, termed '14Cl,' has previously been shown by immunohistological techniques to be present on the surface of the malignant cells within tumour specimens. Western blotting analysis has shown that the majority of primary ovarian cancer specimens and three continuous cell lines derived therefrom express 14Cl; other tissue types were negative. Preliminary biochemical characterization has been carried out, which shows that the 14Cl antigen has a molecular weight range of 25-32 kD and an isoelectric point from pI 6.3 to 6.8. We believe that the 14Cl antigen is immunologically relevant to ovarian cancer patients and may therefore represent a novel target for both active and passive immunotherapy.

Full text

PDF
92

Images in this article

94Fig. 1
on p.94

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Al-Azzawi F., Stimson W. H., Govan A. D. Human antibodies to ovarian cancer antigens secreted by lymphoblastoid cell lines. J Clin Lab Immunol. 1987 Feb;22(2):71–75. [PubMed] [Google Scholar]
  2. Bast R. C., Jr, Klug T. L., Schaetzl E., Lavin P., Niloff J. M., Greber T. F., Zurawski V. R., Jr, Knapp R. C. Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen. Am J Obstet Gynecol. 1984 Jul 1;149(5):553–559. doi: 10.1016/0002-9378(84)90035-8. [DOI] [PubMed] [Google Scholar]
  3. Cote R. J., Morrissey D. M., Houghton A. N., Thomson T. M., Daly M. E., Oettgen H. F., Old L. J. Specificity analysis of human monoclonal antibodies reactive with cell surface and intracellular antigens. Proc Natl Acad Sci U S A. 1986 May;83(9):2959–2963. doi: 10.1073/pnas.83.9.2959. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Ey P. L., Ashman L. K. The use of alkaline phosphatase-conjugated anti-immunoglobulin with immunoblots for determining the specificity of monoclonal antibodies to protein mixtures. Methods Enzymol. 1986;121:497–509. doi: 10.1016/0076-6879(86)21050-2. [DOI] [PubMed] [Google Scholar]
  5. Gallagher G., Christie J. F., Stimson W. H., Guy K., Dewar A. E. T-24.B-cell differentiation factor induces immunoglobulin secretion in human B cells without prior cell replication. Immunology. 1987 Apr;60(4):523–529. [PMC free article] [PubMed] [Google Scholar]
  6. Kan-Mitchell J., Imam A., Kempf R. A., Taylor C. R., Mitchell M. S. Human monoclonal antibodies directed against melanoma tumor-associated antigens. Cancer Res. 1986 May;46(5):2490–2496. [PubMed] [Google Scholar]
  7. Kjeldsen T. B., Rasmussen B. B., Rose C., Zeuthen J. Human-human hybridomas and human monoclonal antibodies obtained by fusion of lymph node lymphocytes from breast cancer patients. Cancer Res. 1988 Jun 1;48(11):3208–3214. [PubMed] [Google Scholar]
  8. Mattes M. J., Look K., Furukawa K., Pierce V. K., Old L. J., Lewis J. L., Jr, Lloyd K. O. Mouse monoclonal antibodies to human epithelial differentiation antigens expressed on the surface of ovarian carcinoma ascites cells. Cancer Res. 1987 Dec 15;47(24 Pt 1):6741–6750. [PubMed] [Google Scholar]
  9. Sakakibara K., Ueda R., Ohta M., Nakashima N., Tomoda Y., Takahashi T. Three novel mouse monoclonal antibodies, OM-A, OM-B, and OM-C, reactive with mucinous type ovarian tumors. Cancer Res. 1988 Aug 15;48(16):4639–4645. [PubMed] [Google Scholar]
  10. Sikora K., Alderson T., Nethersell A., Smedley H. Tumour localisation by human monoclonal antibodies. Med Oncol Tumor Pharmacother. 1985;2(2):77–86. doi: 10.1007/BF02934852. [DOI] [PubMed] [Google Scholar]
  11. Umbach G. Review of tumor markers for ovarian cancer. Med Hypotheses. 1984 Mar;13(3):329–339. doi: 10.1016/0306-9877(84)90166-x. [DOI] [PubMed] [Google Scholar]
  12. Ward B. G., Wallace K. Localization of the monoclonal antibody HMFG2 after intravenous and intraperitoneal injection into nude mice bearing subcutaneous and intraperitoneal human ovarian cancer xenografts. Cancer Res. 1987 Sep 1;47(17):4714–4718. [PubMed] [Google Scholar]
  13. Ward B., Mather S., Shepherd J., Crowther M., Hawkins L., Britton K., Slevin M. L. The treatment of intraperitoneal malignant disease with monoclonal antibody guided 131I radiotherapy. Br J Cancer. 1988 Nov;58(5):658–662. doi: 10.1038/bjc.1988.280. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES